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Abstract
Background: Few placebo controlled studies for sublingual immunotherapy (SLIT) have 
been performed so far in Latin America, and some issues like treatment scheme and 
doses remain uncertain
Objective: to asses improvement in nasal, pharyngeal and ocular symptoms with low 
doses of SLIT to Dermatophagoides pteronyssinus comparing it with a placebo, in a 
Mexican population with allergic rhinitis (AR).
Methods: a prospective, double-blind placebo-controlled, randomized study, with 32, 
patients with chronic, moderate to severe AR; 16 patients were treated with SLIT and 
16 with placebo for 6 months with a total dose of D. pteronyssinus (Der p1) of 50.4 
mcg. Nasal, pharyngeal and ocular symptoms were monitored using a symptoms diary 
to evaluate the degree of improvement and reduction in the use of medication.
Results: Significant lower symptom and drug scores were found in SLIT group where 
85% of patients showed clinical improvement. On the placebo group, 24% of patients 
improved and 76% had no response or worsened; 94% of patients on SLIT required less 
symptomatic medication compared with the placebo group. There was a reduction in 
positivity to cutaneous test to D. pteronyssinus in 50% of the patients on SLIT, whereas 
placebo patients remained all positive
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Conclusions: A low dose, six-month schedule of SLIT with specific allergen produces a 
significant reduction in all nasal, pharyngeal and ocular symptoms, and a reduction of 
medication use. No adverse reactions were observed with this scheme.
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Introduction
Allergic rhinitis (AR) is an inflammatory disease of 
the nose that is mediated by IgE after the repeated 
exposure to an allergen, mainly through inhalation 
which produces nose, eye and pharyngeal symptoms.1,2 
Although it is generally not considered to be a severe 
disorder, the socioeconomic costs of AR are substan-
tial. AR is a major problem of public health affecting 
up to 24% of the adult population and up to 42% of 
the pediatric population. Four hundred million persons 
worldwide have allergic rhinitis. In addition up to 70% 
of persons have reported having asthma have also re-
ported having AR.3
In recent years, in addition to traditional 
subcutaneous immunotherapy (SCIT)4,5,6 sublingual im-
munotherapy (SLIT) has become a standard treatment 
for both children and adults.7,8 Its efficacy has been 
evaluated and the WHO (World Health Organization) 
has approved its clinical use9 SLIT has become popular 
in Europe, Asia and Australia and is becoming increa-
singly so in the United States.10 Nevertheless, despite 
its ever increasing use in Latin America, there have 
only been a few double-blind, placebo-controlled 
(DBPC) clinical studies regarding the efficacy of SLIT 
in Latin American populations.11 To date, there are still 
some uncertain issues with SLIT regarding the magni-
tude of its clinical efficacy on allergic rhinitis, the 
length of treatment and the standard dose to be used. 
Efficacy of SLIT is achieved a doses ranking between 
2-500 times of those used for SCIT.12,13
The aim of this study was to assess the use of SLIT in 
adult, Mexican patients with AR due to house dust mite 
Dermatophagoides pteronyssinus, using a low doses sche-
me during a 6 month period (24 weeks). We evaluated 
efficacy in regard of symptom reduction, relief medica-
tion use, adverse reaction to therapy and compliance to 
this SLIT scheme.
Inmunoterapia sublingual a dosis bajas en pacientes con rinitis alérgica en un 
estudio doble ciego controlado con placebo
Resumen
Antecedentes: Hay estudios que demuestran el efecto benéfico de la inmunoterapia 
sublingual (SLIT) para el tratamiento de la rinitis alérgica, pero solo algunos de és-
tos fueron realizados doble ciego placebo controlados. En Latinoamérica se realizan 
actualmente esquemas de tratamiento con SLIT pero hay todavía discusión sobre el 
mejor esquema de dosis, para lo cual se requiere de mayor cantidad de estudios doble 
ciego placebo controlados. 
Objetivo: Evaluar la efectividad sintomática con el uso de bajas dosis de Inmunote-
rapia sublingual (SLIT) con Dermatophagoides pteronyssinus en un grupo de pacientes 
mexicanos con rinitis alérgica.
Métodos: Estudio aleatorizado, prospectivo doble ciego, placebo controlado con 32 pa-
cientes con rinitis alérgica crónica moderada-severa persistente, 16 tratados con SLIT 
y 16 con placebo por 6 meses, con dosis total de Dermatophagoides pteronyssinus de 
50.4 microgramos. Se monitorizaron los síntomas nasales, oculares y faríngeos usando 
un diario de síntomas evaluando la mejoría sintomática y reducción en el uso de me-
dicación sintomática, se evaluó la reducción en la reactividad cutánea, la reducción 
en la eosinofilia en sangre y mucosa nasal, y se valoraron las reacciones adversas y el 
apego al tratamiento.
Resultados: Hubo reducción significativa sintomática en el 85% de pacientes tratados 
con SLIT. 94% de los pacientes con SLIT redujeron el uso de medicación sintomática. 
Hubo reducción en la reactividad cutánea en el grupo tratado con SLIT en un 50% de 
los casos, .Todos los resultados fueron estadísticamente significativos. Hubo apego al 
tratamiento en 100% y no se reportaron reacciones adversas. 
Conclusiones: El tratamiento de la rinitis alérgica con SLIT a baja dosis en un esquema 
de 6 meses con Dermatophagoides pteronyssinus produce una significativa reducción en los 
síntomas nasales, oculares y faríngeos y una reducción en el uso de medicación sinto-
mática, reducción en la reactividad cutánea a éste ácaro, buen apego al tratamiento 
y sin efectos adversos. 
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Material and methods
This study was double-blind, placebo-controlled (DBPC), 
and randomized and was approved by the ethics and 
research committee of the Faculty of Medicine and 
University Hospital of UANL in Monterrey, Mexico in 
2001-2002. We included adult patients with diagnosis of 
chronic, moderate to severe AR: 22 male (69%) and 10 
female (31%) patients aged from 18 to 40 years. The de-
mographics of the patients are shown in Table 1.
All of the patients understood the study and signed 
the informed consent letter. The inclusion criteria were: 
1) a history of moderate to severe AR without seasonal 
pattern and according to ARIA,2 2) a positive skin (++ 
or greater) test for Dermatophagoides pteronyssinus 3) 
a positive IgE test by immunoenzymatic assay at levels 
higher than 300 UI) specific to D. pteronyssinus. 4) eosi-
nophilia higher than 5% in both nose mucosa and blood, 
5) elevated serum, total IgE levels, 6) willingness to par-
ticipate in the study and 7) a willingness and commitment 
to compliance. 
Exclusion criteria were: 1) previous immunothera-
py treatment up to two years prior to the study, 2) 
use of local or systemic steroids or, chromoglycate or 
antihistaminic medication up to one month before the 
start of study, 3) pregnancy and 4) lack of commitment 
to compliance. 
Clinical evaluation
A complete clinical evaluation and clinical history was 
made at the start of the study at 30 days, and at weeks 
6, 12 18 and 24. As previously mentioned all of the patients 
were selected according to ARIA2 and all of the patients re-
quired medication for the control of AR symptoms. 
Symptom scores 
The patients were instructed to complete a symptom 
diary, which was filled up once at the end of the day, on 
a daily basis throughout the study, for a record of nasal, 
pharyngeal and ocular symptoms, and the occurrence of 
any adverse symptoms and compliance of the doses.
Twelve symptoms were evaluated: a) nasal (nasal obs-
truction, itching, rhinorrhea and sneezing), b) pharyngeal 
(pharyngeal itching, pharyngeal pain, sore throat and re-
tronasal discharge) and c) ocular (eye redness, sore eye, 
ocular itching and tearing). The symptoms were recorded 
in a symptom-diary designed for this purpose and the symp-
toms varied from patient to patient accordingly the 
number and severity of symptoms; we added only the se-
verity of symptoms to Table 6, the patients had variations 
of symptoms in the number and severity; we added only 
the severity of symptoms.
The diary was given to the patients for accurate record 
keeping at each of the four evaluation visits throughout 
the 24 week study and they recorded symptoms based on 
their presence and severity. Symptoms were graded as: 
negative (0), mild (1), moderate (2) and severe (3) (Table 
2) Patients were required to record their drug intake and 
any symptoms or discomfort, local or systemic, possibly 
related to treatment, in the diary. 
Skin tests
A percutaneous test for 24 aeroallergens was performed, 
and included Dermatophagoides pteronyssinus. The reac-
tion was read after 20 minutes and was then compared 
against the positive controls histamine and the negati-
ve control diluent solution. The reaction size was graded 
from 0 to +++. Skin tests were performed again at Stage 4 
for an evaluation of change in skin reactivity. 
Immunoglobulin E levels
Total serum IgE was measured by a commercial ELISA–
sandwich test (Sanofi-Pasteur, France). Specific IgE levels 
to house dust mite Dermatophagoides pteronyssinus 
(made only for the purpose of meeting diagnostic inclu-
sion criteria) was produced in an independent laboratory.
Eosinophil count in blood and nasal mucosa
Nasal cytology was performed using the technique des-
cribed elsewhere.14 Eosinophilia in the nasal mucosa 
membrane was graded by the number of cells in each 
microscopic field and the scores ranged from 0 to +++. 
Eosinophilia in blood was determined by automated 
means.
Allergen preparation
The allergen extract of D. pteronyssinus prepared for 
treatment was made by the Allergen Laboratory of the 
Table 1. Main demographic and characteristic features of ran-
domized patients.
Adult population SLIT group 
(n= 16)
Placebo group 
(n=16)
P value
Average age a, d 25 +- 7.1c 27 +- 7.8c p= 0.4537
Adults a n16 (50%) n16 (50%)
Male b n12 (75%) n10( 62%) p=0.4456
Female b n4 (25%) n6 (38%) p=0.4456
Duration of rhinitis 
(years)
12 +- 7.5c 12 +- 5.4c  p= 1
Rhinitis score/
patient 
initial-stage 0
19.6 +- 5.9c 19.1 +- 6.5c p= 0.844
IgE serum level
initial-stage 0
387 +- 259.5c 339 +- 262.6c p= 0.608
RAST 
D.pteronyssinus 
Positive Positive
a Data are given as number (percentage) of each group.
b Using the Chi square test.
c Data are given as mean +- SD(standard deviation).
d t test.
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Immunology Service University Hospital of UANL The base 
solution was prepared a concentration allergen protein of 
1mg/ml, from which all of the diluted concentrations for 
treatment were derived. The active SLIT was scheduled 
and administered as described below, in the form of three 
drops applied sublingually. This routine was performed 
daily (in the morning before breakfast) and the patients 
were told to hold the drops sublingually for one minute, 
prior to swallowing Table 3.
Treatment
The treatment was given for 24 weeks. After an initial pe-
riod of 30 days (wash-out period), patients with a diagnosis 
of AR, were randomly divided in two groups, one with 16 
patients who received the active SLIT treatment and a se-
cond with 16 patients who received the placebo treatment. 
All patients were allowed to use antihistaminic and nasal 
steroid medication for symptoms control and were advised 
to accurately record its use in the symptoms diary. Record 
keeping was used to assess the need for medication at the 
end of the treatment. The treatment of the SLIT group was 
administered in 4 stages with increasing doses given as fo-
llows: a) recruiting period (no treatment) b) wash-out stage 
(no treatment) c) Stage 0: 0.15 mcg/day dose for 6 weeks, 
d) Stage 1: 0.25 mcg/day dose for 6 weeks e) Stage 2: 0.35 
mcg/day dose for 6 weeks, f) Stage 3: 0.45 mcg/day dose 
for 6 weeks and g) Stage 4 (end of study). At the end of each 
stage (including the wash-out period) a new symptom dairy 
was given to the patients. Eosinophil counts and scratch tests 
were done at the end of the wash-out period and at Stage 
4. The placebo group followed the same schedule, but the 
flasks given to these patients were prepared only with di-
luent solution (Table 3).
Compliance
In the symptoms diary, patients had to fill a daily form 
to assess compliance. We evaluated patients’ compliance 
reviewing the dairies every six weeks, to detect any failu-
re or interruption of treatment.
Statistical methods 
To determine the number of patients to be included in 
the study for a significant difference between groups, 
we calculated the number of patients for a = 0.05 and b 
= 0.80 to be 14 per group. For possible dropouts during 
the study, we choose a samples size of 16. The variables 
with parametric distribution were expressed as mean and 
standard deviation; those with non-parametric distribu-
tion are presented as median and rank. Comparison of 
mean were made by ´Students T test. Comparison of me-
dian was made by Mann-Withney test and for proportion, 
Table 2. Symptoms diary and grading score.
Severity Nose Pharinx Eyes
 0= none No symptoms No symptoms No symptoms
 1= mild
Occasional symptoms; 
less than 3 h/day,
less than 5 sneezes/day.
Bleeding 2 times/month. 
No olfactory loss.
Occasional symptoms,
Less than 3 h/day
Occasional symptoms
Less than 3 h/day
 2= moderate
Symptoms for more 
than 3h/day or half a day,
5 to 15 sneezes/day,
Occasional olfactory loss
Bleeding 3 times/month
Symptoms for more than 
3 h/day or half a day
Symptoms for more than 
3 h/day or half a day
 3 = severe
Symptoms daily, 
more than 12 h/day or the whole day
More than 15 sneezes/day
Olfactory loss
Bleeding more than 4 times/month
Symptoms daily, more than 
12 h/day or the whole day
Symptoms daily, more than 
12 h/day or the whole day
Table 3. SLIT schedule for the entire active treatment. The 
placebo group was scheduled exactly as the SLIT group. See 
text for details
Stages Characteristics
Wash-off stage
Four weeks without medication. Clinical history 
collected. Explanation about symptom diary and start 
of recording
Stage 0
Six weeks. Start of SLIT treatment. Three drops 
sublingual at 0.15 mcg/dose (total dose for the stage: 
6.3 mcg) 
Stage 1
Six weeks. Three drops sublingual at 0.25 mcg/dose 
(total dose for the stage: 10.5 mcg)
Stage 2
Six weeks. Three drops sublingual at 0.35 mcg/dose 
(total dose for the stage: 14.7 mcg)
Stage 3
Six weeks. Three drops sublingual at 0.45 mcg/dose 
(total dose for the stage: 18.9 mcg)
Stage 4
End and evaluation of symptoms-dairies for each 
patient.
Cumulative final doses: 50.4 mcg
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x2 test was used. For comparisons a significance level of 
0.05 was used The statistical management of data was 
performed by a licensed program STAT-IC-2008
Results
Demographic characteristics
We screened 166 patients with symptoms of AR and 32 were 
selected who met the criteria to be included in the study. 
The features of the groups are shown in Table 1. No diffe-
rences were observed between the two groups in terms 
of patients features (age, sex and duration of disease) 
as confirmed by statistic analysis. There were no dro-
pouts from the two groups, so the final number of each 
group was 16. Analysis of symptom diary showed neither 
systemic nor local side effects recorded during SLIT. Ba-
sed on the clinical records and the inclusion criteria the 
AR was considered to be produced by D pteronyssinus, 
a household allergen affecting the indoor population. 
Furthermore, there were no exacerbation of symptoms 
that could be attributed to seasonal allergens, confir-
ming our inicial observation that no other major seasonal 
allergens were identified as leading symptom cause in the 
selected patients.
Symptom scores
We compared the symptom data recorded at the wash-out 
stage with that of Stage 4 after 24 weeks of treatment. 
Analysis of the symptoms diaries showed changes in the 
intensity and frequency of symptoms, as shown in Table 
4; differences between the active and placebo groups 
were recorded with regard to nasal, ocular and pharyn-
geal symptoms. Clear, statistically significant differences 
were observed between SLIT and placebo group. Table 
4 show differences between the two groups with regard 
to nasal symptoms, in which a statistically significant 
difference was recorded. Furthermore, a comparison of 
symptoms between groups showed a significant improve-
ment in the active SLIT group versus the placebo group 
regarding nasal pharyngeal and ocular symptoms.
Medication scores
Regarding the use of medication for symptoms control, 
there was a significant difference between groups: 94% of 
patients in the active group reported a reduction or wi-
thdrawal of symptomatic drug use during the treatment 
period of 24 weeks, whereas it happened in the 20% of 
patients in the placebo group (Table 5). 
Skin reactivity
Skin reactivity was measured from 0 to +++ and 
tested at the start and end of treatment schedule: the 
active group showed a reduction in reactivity or a negati-
ve test result in 50% of the SLIT treated patients, whereas 
in the placebo group no patients had reduced reactivity 
Table 4. Changes in pharyngeal, nose and eye symptoms sco-
res, SLIT vs Placebo group. Improvement comparison between 
the two groups showed statistically significant differences (* 
p<0.005) both in individual symptoms and as a total score of 
symptoms. 
  SLIT   PLACEBO  
  Improvement   Improvement  
   Patients % Patients %
Nose symptoms        
Sneezing 14 88* 4 25
Obstruction 14 88* 5 31
Itching 12 86* 5 31
Rhinorrhea 14 88* 4 27
Total  88*  29
Pharyngeal 
symptoms
       
Sore throat 6 86* 2 20
Itching 10 91* 6 46
Pain 4 80* 1 13
Retronasal 
discharge
13 87* 2 14
Total   86*   24
Eye symptoms        
Itching 10 91* 3 30
Tearing 8 80* 1 10
Eye redness 7 78* 1 12
Sore eyes 8 80* 3 33
Total   83*   22
Global 
improvement 
   85%*   24%*
Table 5. Changes in symptomatic medication as scored at Sta-
ge 4 between the SLIT and placebo groups.
Placebo SLIT
n % n %
Same use of drugs as in Stage 0 13 80 * 1 6
Increased use of drugs 0 0 0 0
Decreased use of drugs 3 20 15 94*
TOTAL 16 100% 16 100%
Results are shown both as the number of patients and the percentage 
in each group. 
(*p< 0.005)
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or negative test results. In this latter group all patients 
remained with either enhanced or identical skin reactivi-
ty as when compared to the start of the study (Table 6). 
In eight (50% of patients in the active Group, there was 
a reduction or a negative skin test, whereas eight remai-
ned unchanged. In the placebo Group four patients had 
an augmented reaction whereas 12 remained unchanged. 
Eosinophil count in blood and nasal mucosa
There was no significant difference between the two 
groups regarding eosinophils in the nasal cytology mucous 
mucosa membrane, for in the active SLIT group muco-
sal eosinophils were reduced in 37%, whereas in placebo 
group it was reduced in 25% of patients. However, the 
blood eosinophil count was significantly reduced in the ac-
tive SLIT group in 69% of patients and in placebo group it 
was reduced only in 13% of patients. (Table 7).
Side effects
After the assessment of the symptoms diary of each pa-
tient, we found that SLIT was well tolerated by all 16 
patients studied in the active group. No adverse effects 
were recorded in the placebo group either. In any of the 
clinical evaluations made every six weeks, adverse reac-
tions were recorded by the patients.
Compliance
We evaluated patients’ compliance reviewing the dairies 
every six weeks, and as a whole at the end of the sche-
duled treatment with SLIT /placebo. No patients referred 
failure in the administration of the therapy, or any failure 
or interruption of treatment.
Discussion
The present work is a double-blind, placebo-controlled 
trial (DBPC), which compared the clinical efficacy of SLIT 
in a group of Mexican adults with moderate to severe 
chronic AR. Our results showed a efficacy of SLIT over 
a 24 week period and with standardized doses increa-
sing every 6 weeks. Our results are in agreement with 
the mainstream of DBPC studies on SLIT that have been 
analyzed in several meta-analyses13,15,16,17 and confirm the 
efficacy of this route for desensitization therapy. Thus, 
we have added a study carried out in a Latin American 
population to the body of evidence in favor of SLIT. 
However, some other aspects of SLIT therapy, such as dose 
and time of treatment remain key issues for analysis and 
discussion.18 In the present study we used a doses 3-fold 
higher than the subcutaneous dose starting at 0.15 mcg/
day and increasing every 6 weeks to the end with a dose 
of 0.45 mcg/day (3 times higher than the starting dose). 
In the available studies made from 1986 -2003 of SLIT 
Clinical studies with SLIT from 1986 to 2003 showed va-
riably efficacy from 20% to 50% using different allergens, 
the magnitude of clinical efficacy ranged between 20% 
and 50%, and no severe systemic adverse events were 
reported in the literature over 15 years17 A remarkable fin-
ding was that no patients in this study had any adverse 
effects related to SLIT. This could be attributed to a lower 
dose,19 and may have resulted in the absence of dropouts 
and very good compliance shown by patients. It has been 
recorded that higher doses could be related to a higher 
efficacy of SLIT, but at the same time they may have a 
higher frequency of adverse effects.20,21 According to 
some authors that have reviewed immunotherapy doses, 
SLIT involves doses calculated between 2 and 500 times 
those used for subcutaneous immunotherapy.7,17
Our results with the use of 3 times the corresponding 
doses of SCIT and cumulative doses of 50.4 mcg belong to 
the low dose group and therefore cannot appear to be 
in agreement with the current consensus that the use of 
high doses of allergen is the better way to deliver SLIT 
with good results.22,23 
Passalacqua et al,24 using an 8-month scheme with 
a cumulative Parietaria dose of 16 mcg for AR and as-
thma, showed a significantly improved symptom score 
Table 6. Changes in skin testing reactivity.
Placebo SLIT
n % n %
Decreased reactivity to skin test or 
no reaction
0 0 8 50*
Increased reactivity to skin test or 
no change
16 100 8 50
Total 16 100 16 100
Comparison between Stage 0 and Stage 4,which showed statistically 
significant differences (*p< 0.005).
Table 7. Changes in blood and nasal eosinophil count for each 
group SLIT vs placebo. Comparison between the two groups, 
showed statistically significant differences (*p< 0.005).
Blood eosinophil count
Eosinophils in nasal 
mucosa
 Placebo SLIT Placebo SLIT
 n % n % n % n %
No change 14 87* 5 31* 12 75* 10 63*
Decrease 2 13* 11 69* 4 25* 6 37*
Total 16 100 16 100 16 100 16 100
Comparison between Stage 0 and Stage 4,which showed statistically 
significant differences (*p< 0.005).
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and a reduction in the drug use and nasal neutrophil and 
eosinophil counts. No adverse reactions were recorded. 
Similarly, Purello-D’Ambrosio et al. had positive results 
using a cumulative dose of 12.7 mcg of Parietaria in a 
7-month scheme, with respect to AR and asthma, both 
in the clinical responses and drug scores and without any 
patients reporting adverse effects.24,25 These two studies 
were similar to ours, as we also had positive results using 
a low cumulative doses over a 6 to 8 month period of 
treatment. Our study shows further evidence that low 
doses of SLIT with D pteronyssinus, may provide an effec-
tive alternative to SCIT without any adverse effects. The 
standarization of the doses for SLIT is an important issue 
in need of further study and clear recommendations. One 
factor affecting the standardization of allergen solutions 
for SLIT is the use of different units for the grading of 
potency/activity of allergens. In the extended use of 
SLIT, references to international units (IU), biological 
units, (BU), the index of reactivity (IR), standard thera-
peutic units (STU), allergy units (AU) and the simple w/v 
allergen concentration are made,26 all of them indica-
ting standardized allergens and making the field confusing 
and unclear. This hampers a direct comparison of sche-
mes and schedules for SLIT. Choosing to use micrograms 
/ml concentrations of allergen protein, we deliberately 
used protein doses expressed as weight units, which we 
believe are beyond subjective interpretations or changes 
in biological activity that cannot be easily determined. 
Regardless of the consensus on units to be used in the 
near future in SLIT, it remains to be further determined 
whether the clinical efficacy of SLIT is unequivocally and 
directly proportional to the administered dose.7,16,27,28
Compliance for treatment is another issue that is un-
der debate for SLIT.29 As for any form of immunotherapy, 
compliance is determinant for a successful SLIT scheme.29 
This was again observed in our study were a high com-
pliance by the patients was recorded. Passalacqua et al. 
point out that adherence to SLIT could be expected to be 
lower than in SCIT, for SLIT self-managed by the patient. 
Although a direct comparison of SCIT vs SLIT regarding 
compliance was not done and was not their goal, by stu-
dying compliance on SLIT at 3 and 6 months of treatment 
they found compliance to be satisfactory, with once-daily 
administration and a simple updosing schedule playing a 
relevant role in improving compliance.30 We had no dro-
pouts or irregularities in treatment compliance and all 
patients took all scheduled doses. Interestingly, many 
of our patients were reactive to multiple allergens; ne-
vertheless they had a good response to Dermatophagoides 
monotherapy. This is an important issue that should be 
addressed in further research, SLIT monotherapy could 
be administered in patients with skin positivity to diffe-
rent allergens, but with symptoms to a specific allergen 
that are referred to and related by the patient.
In conclusion, our study shows that this SLIT-scheme is 
effective reducing symptoms, reduction of symptomatic 
drug use and has no adverse reaction.
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